Predict your next investment

Corporation
HEALTHCARE | Drug Development
modernatx.com

See what CB Insights has to offer

Founded Year

2010

Stage

IPO | IPO

Total Raised

$1.961B

Date of IPO

12/7/2018

Market Cap

74.29B

Stock Price

454.60

About Moderna Therapeutics

Moderna Therapeutics (NASDAQ:MRNA) is a Cambridge, Massachusetts-based biotechnology company that is focused on drug discovery and drug development based on messenger RNA. The company creates synthetic mRNA that can be injected into patients to help them create their own therapies.

Moderna Therapeutics Headquarter Location

200 Technology Square

Cambridge, Massachusetts, 02139,

United States

617-714-6500

Latest Moderna Therapeutics News

F.D.A. Authorizes Pfizer Booster Shot for Higher-Risk People

Sep 23, 2021

. to approve a third shot for all recipients of its vaccine who were 16 and older, six months or more after their second injection. Regulators scrambled to collect and review safety and efficacy data fast enough to meet the administration’s goal of offering shots this week. At a dramatic meeting last week, members of the F.D.A.’s outside advisory committee said the available data was too limited to justify additional injections for so many people and voted 16 to 2 against approving Pfizer’s request. Some of the committee’s experts were concerned that Pfizer’s clinical trial results on boosters included only about 300 volunteers, a point that was brought up repeatedly by the C.D.C.’s experts. But the advisory committee voted unanimously for the narrower option reflected in the regulatory decision. Image President Biden attends a virtual global Covid-19 summit on Wednesday from New York. He had hoped to offer a third shot more broadly to adults who had received the Pfizer or Moderna vaccines. Credit...Doug Mills/The New York Times The F.D.A. not only narrowed Pfizer’s request, but authorized the third shot on an emergency basis instead of fully approving it. Understand Vaccine and Mask Mandates in the U.S. Vaccine rules. On Aug. 23, the Food and Drug Administration granted full approval to Pfizer-BioNTech’s coronavirus vaccine  for people 16 and up, paving the way for an increase in mandates in both the public and private sectors. Private companies have been increasingly mandating vaccines  for employees. Such mandates are  legally allowed  and have been upheld in court challenges. Mask rules. The Centers for Disease Control and Prevention in July recommended  that all Americans, regardless of vaccination status, wear masks in indoor public places within areas experiencing outbreaks, a reversal of the guidance it offered in May. See where the C.D.C. guidance would apply , and where states have instituted their own mask policies . The battle over masks has become contentious in some states, with some local leaders defying state bans . New York City. Proof of vaccination is required of workers and customers for indoor dining, gyms, performances  and other indoor situations, although enforcement does not begin until Sept. 13. Teachers and other education workers  in the city’s vast school system will need to have at least one vaccine dose by Sept. 27, without the option of weekly testing. City hospital workers  must also get a vaccine or be subjected to weekly testing. Similar rules are in place for New York State employees. At the federal level. The Pentagon announced that it would seek to make coronavirus vaccinations mandatory for the country’s 1.3 million active-duty troops  “no later” than the middle of September. President Biden announced that all civilian federal employees  would have to be vaccinated against the coronavirus  or submit to regular testing, social distancing, mask requirements and restrictions on most travel. As a practical matter, since the F.D.A. fully approved the Pfizer-BioNTech vaccine as a two-dose regimen last month, physicians have had broad latitude to prescribe a third dose to people they deemed in need of one. Many Americans have already sought extra shots on their own , typically by finding a cooperative pharmacist or pretending to be unvaccinated. “There’s anxiety about this public expectation that everyone should go get a booster,” said Dr. Marcus Plescia, the chief medical officer for the Association of State and Territorial Health Officials, which represents state health agencies. “If we pull back on that, then states are going to get left holding the bag.” Dr. Jesse L. Goodman, a former chief scientist at the F.D.A., said that because of some uncertainty around the benefits of boosters, regulators were right to grant only an emergency clearance for the shots while continuing to study their safety and performance. “A stepwise approach is very judicious,” he said. Some state health officials greeted the F.D.A.’s move enthusiastically. Dr. Clay Marsh, West Virginia’s Covid-19 czar, said that his state’s success vaccinating older residents early meant that they were overdue for extra protection. He also said that strained hospitals in the state could not afford to lose more staff, and that booster doses could protect frontline workers from milder infections that would require them to stay at home. “Anxious would be an understatement,” he said of those waiting for extra shots. “We’ve asked them to be patient with us. We’ve gotten texts and emails from people saying they’re living like hermits again with Delta variant, asking when is it going to be safe.” The decision is the latest in a series of important ones that the F.D.A. is expected to make in the next few weeks. Ahead lie complex decisions on whether to authorize booster shots for recipients of the Johnson & Johnson and Moderna vaccines, whether to authorize the use of Moderna’s vaccine for children ages 12 to 17, and whether to authorize Pfizer-BioNTech’s vaccine for children between the ages of 5 and 11. Top federal health officials have said they needed to publicly announce plans for a booster campaign so that states could prepare for a rollout. But some state officials said it was a challenge to sort out conflicting messages from federal officials. For instance, the president said people should be eligible for a booster eight months after their second shot, but the F.D.A. set the interval at six months. Patrick Allen, the director of the Oregon Health Authority, said that the switch has thrown off the state’s planning and caused officials there to “scramble” to prepare for many more residents who now could be eligible. “We thought at an eight month window we were going to be OK with supply and demand, with our core infrastructure being clinics and pharmacies. But if we have 350,000 people eligible at the beginning, we’re going to have some challenges,” he said, referencing estimates the state has made. At least one county is now preparing to reopen a fairgrounds site for booster doses, he said. Advertisement

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Moderna Therapeutics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Moderna Therapeutics in 3 CB Insights research briefs, most recently on Apr 19, 2021.

Expert Collections containing Moderna Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Moderna Therapeutics is included in 6 Expert Collections, including Synthetic Biology.

S

Synthetic Biology

235 items

Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.

P

Pharma Startups

11,639 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

H

Healthcare Horizons

27 items

Cutting-edge developments in healthcare, and the startups behind them, that are just beginning to impact the world. This collection includes companies covered in the Healthcare Horizons briefing and accompanying report.

C

Cancer Therapeutics

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

S

Sequoia Capital China Investments 2018-2019

149 items

R

Regenerative Medicine

1,767 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Moderna Therapeutics Patents

Moderna Therapeutics has filed 139 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • RNA
  • Gene expression
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/11/2014

6/8/2021

Transcription factors, Molecular biology, Biotechnology, Genetic engineering, Genetics

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

7/11/2014

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

6/8/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Transcription factors, Molecular biology, Biotechnology, Genetic engineering, Genetics

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Moderna Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Moderna Therapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.